Published in Clin Exp Immunol on May 01, 1986
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (1985) 21.57
AIDS--an immunologic reevaluation. N Engl J Med (1984) 3.53
A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med (1984) 3.41
NIH conference. The acquired immunodeficiency syndrome: an update. Ann Intern Med (1985) 2.68
The acquired immune deficiency syndrome. Clin Exp Immunol (1984) 1.62
The human thymus microenvironment: heterogeneity detected by monoclonal anti-epithelial cell antibodies. Immunology (1985) 1.56
Demonstration of an intrathymic defect in a case of severe combined immunodeficiency disease. N Engl J Med (1975) 1.46
Human bone marrow cells positive for terminal deoxynucleotidyl transferase (TdT), HLA-DR, and a T cell marker may represent prothymocytes. J Immunol (1985) 1.11
Induction of lymphocyte differentiation by epidermal cultures. J Invest Dermatol (1981) 1.04
Induction of T-lymphocyte differentiation by thymic epithelial cell monolayers. Clin Immunol Immunopathol (1978) 1.01
How unique is the thymus? Conditioned media from thymus and tonsil epithelial cultures share biological activities in T-cell maturation. Clin Immunol Immunopathol (1981) 0.94
Lymphocyte status of lymph node and blood in acquired immunodeficiency syndrome (AIDS) and AIDS-related complex disease. J Pathol (1985) 0.93
The thymus in "bare lymphocyte" syndrome: significance of expression of major histocompatibility complex antigens on thymic epithelial cells in intrathymic T-cell maturation. Hum Immunol (1985) 0.92
Presence of thymosin-like factors in human thymic epithelium conditioned medium. Int J Immunopharmacol (1979) 0.89
Successful restoration of immunity in the DiGeorge syndrome with fetal thymic epithelial transplant. Arch Dis Child (1978) 0.86
Thymic transplantation for relief of immunodeficiency diseases. Surg Clin North Am (1979) 0.79
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol (1989) 8.32
Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science (1999) 7.66
Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science (1997) 5.55
Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med (1998) 5.08
Disruption of mouse RAD54 reduces ionizing radiation resistance and homologous recombination. Cell (1997) 4.78
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis (1995) 4.60
Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet (1986) 4.54
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis (1992) 4.21
Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet (1989) 4.19
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med (2001) 3.74
Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med (2000) 3.70
Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis (1996) 3.68
Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med (1990) 3.61
Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest (1988) 3.59
Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J (Clin Res Ed) (1986) 3.27
Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J Infect Dis (1992) 3.16
SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation (1997) 2.80
Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus. Br Med J (Clin Res Ed) (1986) 2.75
Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet (1998) 2.67
Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet (1990) 2.50
Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci U S A (1998) 2.39
Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects. Lancet (1988) 2.38
Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS (1998) 2.19
Antigenemia and antibody titers to core and envelope antigens in AIDS, AIDS-related complex, and subclinical human immunodeficiency virus infection. J Infect Dis (1987) 2.17
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS (2000) 2.14
Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS (1999) 2.09
Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. J Infect Dis (1988) 2.06
The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS (1992) 2.06
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS (2001) 2.03
Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia. Br Med J (Clin Res Ed) (1987) 2.02
[Therapeutic options for HIV infection should lead to increased utilization of HIV tests]. Ned Tijdschr Geneeskd (1999) 2.01
Somatic mutations in the variable regions of a human IgG anti-double-stranded DNA autoantibody suggest a role for antigen in the induction of systemic lupus erythematosus. J Exp Med (1991) 1.95
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet (1998) 1.88
Ongoing HIV dissemination during HAART. Nat Med (1999) 1.85
Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS (1993) 1.85
Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS (2001) 1.81
Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum (1995) 1.80
Prevalence of Campylobacter-associated diarrhea among patients infected with human immunodeficiency virus. Clin Infect Dis (1997) 1.80
Long-term followup of patients with Sjögren's syndrome. Arthritis Rheum (1996) 1.76
OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol (2001) 1.75
Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2000) 1.68
Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS (1999) 1.64
Mutation analysis of the Bruton's tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice. Hum Mol Genet (1994) 1.62
Response to cytarabine in progressive multifocal leucoencephalopathy in AIDS. Lancet (1991) 1.62
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis (2001) 1.62
Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis (1999) 1.61
Effects of protease inhibitors on the course of CMV retinitis in relation to CD4+ lymphocyte responses in HIV+ patients. Br J Ophthalmol (1998) 1.57
The human thymus microenvironment: heterogeneity detected by monoclonal anti-epithelial cell antibodies. Immunology (1985) 1.56
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS (2000) 1.56
Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother (1993) 1.56
Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis (1998) 1.55
Sjögren's syndrome in patients with chronic idiopathic axonal polyneuropathy. J Neurol Neurosurg Psychiatry (1997) 1.54
Rapid disease progression in human immunodeficiency virus type 1-infected individuals with adverse reactions to trimethoprim-sulfamethoxazole prophylaxis. Clin Infect Dis (1997) 1.51
The true function of the thymus? Immunol Today (1989) 1.50
B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia. J Biol Chem (1994) 1.48
HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS (1992) 1.47
Heterogeneity of epithelial cells in the human thymus. An ultrastructural study. Cell Tissue Res (1984) 1.47
Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection. AIDS (2000) 1.47
Binding of human immunodeficiency virus type-1 to follicular dendritic cells in vitro is complement dependent. J Immunol (1993) 1.45
Recognition of human 60 kD heat shock protein by mononuclear cells from patients with juvenile chronic arthritis. Lancet (1991) 1.45
Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis (1993) 1.45
Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheum Dis (1988) 1.44
T-cell receptor V beta-family usage in primary cutaneous and primary nodal T-cell non-Hodgkin's lymphomas. J Invest Dermatol (1992) 1.43
Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains. AIDS (2001) 1.42
Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HIV-1)-infected men. J Clin Immunol (1990) 1.42
No histological evidence for cytotoxic T cells in destruction of lymph-node follicle centres after HIV infection? AIDS (1991) 1.42
Monitoring rejection after heart transplantation: cytoimmunological monitoring on blood cells and quantitative birefringence measurements on endomyocardial biopsy specimens. J Clin Pathol (1990) 1.41
IgA-deposits in cutaneous blood-vessel walls and mesangium in Henoch-Schönlein syndrome. Lancet (1973) 1.40
Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ (1989) 1.39
Breaking of transplantation tolerance after reduction of immunosuppression. J Thorac Cardiovasc Surg (1993) 1.39
[Virological evaluation of treating HIV-infected patients with (combinations of) antiretroviral drugs at the Amsterdam Academic Medical Center, 1996/'97]. Ned Tijdschr Geneeskd (1998) 1.39
[Primary HIV-infection: infectious mononucleosis-like presentation with treatment options]. Ned Tijdschr Geneeskd (1999) 1.39
The alkaloid sinomenine lacks efficacy in rat heart transplantation. Transpl Int (2000) 1.39
Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J Acquir Immune Defic Syndr (2001) 1.37
Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. AIDS (1998) 1.34
Prevention of relapses in systemic lupus erythematosus. Lancet (1995) 1.33
Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis (1999) 1.32
Host cell membrane proteins on human immunodeficiency virus type 1 after in vitro infection of H9 cells and blood mononuclear cells. An immuno-electron microscopic study. J Gen Virol (1993) 1.31
Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis (1995) 1.29